Clinical Trial

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Study acronym: BiPAVE-001
Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
BIPAVE-001 is a Phase 1-2 study for evaluating the safety, pharmacokinetics (PK), and efficacy of AI-081 in solid tumors.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2024-10-08; most recent amendment 2026-04-08.
Status change: Not Yet Recruiting → Recruiting 2025-02-26
Trial Details
NCT Number NCT06635785
Lead Sponsor OncoC4, Inc.
Conditions Advanced Solid Tumor
Enrollment 387 participants
Start Date 2025-03-26
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-04-09